Hofseth BioCare Prospectus Cleared, 32.8M Shares to Trade

Hofseth BioCare ASA said Norway's Financial Supervisory Authority approved the listing prospectus tied to its June 2026 private placement, clearing the way for 32,819,999 Tranche 2 shares to move onto the company's ordinary ISIN and trade on Euronext Oslo Børs. The placement, priced at NOK 1.30 per share, issued 111,154,608 new shares and raised gross proceeds of about NOK 144.5 million. The company announced the approval on 9 October 2026.

Context — Why the Hofseth BioCare Prospectus Approval Matters Now

The event closes a gap that has sat open since the summer. The private placement was announced on 28 June 2026, and the company split settlement into two tranches rather than delivering all shares as immediately tradable.

Tranche 1 covered 78,334,609 shares, issued under a board authorization and delivered as tradable stock. Tranche 2, the remaining 32,819,999 shares, required shareholder sign-off, which came at an extraordinary general meeting on 30 July 2026.

Those second-tranche shares were issued but parked on a separate, non-tradable ISIN. Holders could not sell them on the main line until a prospectus was approved and published. That is the constraint the regulator's sign-off removes.

The company's own framing of the delay is procedural, not operational. It said the Listing Shares were delivered on the separate ISIN "pending approval and publication of a listing prospectus." No business disruption is described in the report.

For a small-cap on Oslo Børs, the practical issue is liquidity. A block of roughly 32.8 million shares sitting outside the tradable float distorts the visible supply. Once transferred, that overhang joins the ordinary line, and the quoted share count reflects the full placement.

The timing also matters for index and data providers. Vendors that track free float and tradable share counts update only after shares sit on the main ISIN. Until then, screens can understate the company's listed share base.

Hofseth BioCare describes itself as a Norwegian consumer and pet health company built on sustainability, optimal use of natural resources and full traceability. It upcycles salmon-industry side streams, converting fresh filleted salmon from a waste product into health ingredients. The report gives no revenue, margin or cash figures, so the placement's effect on the balance sheet cannot be sized from the disclosure alone.

Data — What the Numbers Show

The headline figures are fixed and simple. The private placement priced every new Ordinary Share at NOK 1.30. The company issued 111,154,608 shares across the two tranches, raising gross proceeds of approximately NOK 144.5 million.

The tranche split is the detail that drives the trading mechanics. Tranche 1 held 78,334,609 shares, or about 70.5% of the placement. Tranche 2 held 32,819,999 shares, roughly 29.5%.

Item	Tranche 1	Tranche 2
Shares	78,334,609	32,819,999
Issue basis	Board authorization	EGM, 30 July 2026
Initial tradability	Immediately tradable	Non-tradable ISIN
Current status	Trading	Moving to ordinary ISIN

Before the approval, roughly 32.8 million placement shares were issued but not tradable on the main line. After publication of the prospectus, the full 111.15 million shares sit on the ordinary ISIN.

The report does not disclose the company's total shares outstanding, so the placement's percentage of the enlarged share capital cannot be calculated from this disclosure. It also gives no price comparison, no discount to any reference price, and no valuation multiple.

What the NOK 1.30 price does establish is the cash the company raised per share. Multiply the fixed price by the share count and the gross figure lands at roughly NOK 144.5 million, matching the company's stated total. That is the only arithmetic the report supports.

No peer comparison is available in the report. Hofseth BioCare trades under the ticker "HBC" on Oslo Børs, and the company confirmed that listing in its own description.

Analysis — What It Means for Markets and the HBC Ticker

The immediate mechanical effect is a wider tradable float. Shares that were locked on a separate ISIN become sellable on the main line, which raises the number of shares available to trade without changing the company's economics.

That cuts two ways. A larger float generally improves liquidity and can narrow bid-ask spreads, which helps institutional participation. It also removes a technical scarcity that can hold a price above where free supply would sit.

The counter-argument is that the transfer is a technicality, not new information. Investors have known since June that Tranche 2 existed and since July that shareholders approved it. The approval and publication were the expected next steps, so the tradable supply was already priced by anyone tracking the file.

Flow direction is the open question. Holders who received non-tradable shares in July now have the option to sell for the first time. Whether that supply meets demand depends on the buyer base, and the report gives no holder breakdown, no lock-up terms and no anchor-investor detail.

The adviser lineup is thin in the disclosure. Advokatfirmaet CLP DA acted as legal adviser to the company. No financial adviser, bookrunner or manager is named in the report, and the company did not disclose placement fees or net proceeds.

Sector exposure is narrow. Hofseth BioCare sits in the salmon upcycling niche, turning side streams into ingredients it markets as ProGo, a mix of bioactive peptides and collagen; OmeGo, a whole salmon oil containing the fatty acid fractions found in fish; and CalGo/NT-II salmon bone powder for bone and joint health. The report cites no peer companies and no sector index, so no relative valuation can be drawn from it.

Outlook — What to Watch Next

Three things follow from the approval. First, the Listing Shares must actually be transferred to the ordinary ISIN, and the report describes that as happening "following publication of the Prospectus" without naming a settlement date. Second, trading in those shares on Euronext Oslo Børs begins only after the transfer.

The prospectus itself is the third item. It is available on the company's website, and it is the document that carries the risk factors, financial statements and share-capital detail the announcement omits. Anyone sizing the placement needs the prospectus, not the press release.

The report names no price levels, no support or resistance, and no moving averages. It also gives no forward guidance, no production targets and no revenue outlook. Those gaps stay gaps until the company discloses them.

For contact, the company lists CEO Jon Olav Ødegård, with phone +47 936 32 966 and email [email protected]. The disclosure is made under Section 5-12 of the Norwegian Securities Trading Act.

Frequently Asked Questions

What does the prospectus approval mean for Hofseth BioCare shareholders?

It converts 32,819,999 previously issued but non-tradable shares into freely tradable stock on the company's ordinary ISIN. Holders of those Tranche 2 shares, delivered after the 30 July 2026 extraordinary general meeting, can trade them on Euronext Oslo Børs once the transfer completes. Shareholders holding Tranche 1 stock, which was delivered as immediately tradable, see no change to their position from this step.

Why were the Tranche 2 shares non-tradable in the first place?

The company split the private placement into two tranches with different legal bases. Tranche 1 relied on an existing board authorization, so those 78,334,609 shares could be delivered as tradable immediately. Tranche 2 needed shareholder approval at the 30 July 2026 EGM, and the shares were held on a separate ISIN until a listing prospectus was approved and published.